S'abonner

A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis - 09/08/11

Doi : 10.1016/j.jaad.2005.11.1091 
Robert M. Knobler, MD a, , Lars E. French b, Youn Kim, MD c, Emil Bisaccia, MD d, Winfried Graninger, MD e, Hesam Nahavandi, MD a, Frank J. Strobl, MD, PhD f, Edward Keystone, MD g, Marilyn Mehlmauer, MD h, Alain H. Rook, MD i, Irwin Braverman, MD j

in the name of the Systemic Sclerosis Study Group

  Photopheresis Systemic Sclerosis Study Group members: Ann G. Martin, MD, Washington University School of Medicine, St Louis, Mo; Neil P. Smith, MD, St Thomas Hospital, London, UK (deceased); George P. Stricklin, MD, PhD, Tennessee Valley Healthcare System (Murfreesboro) and Vanderbilt University (Nashville); Bruce U. Wintroub, MD, University of California-San Francisco; Brian Jegasothy, MD, University of Pittsburgh, Pennsylvania (deceased); and David Fivenson, MD, Henry Ford Hospital, Detroit, Mich.

a From the Department of Dermatology, Medical University of Vienna 
b Department of Dermatology, Geneva University Hospital 
c Department of Dermatology, Stanford University School of Medicine 
d Morristown Memorial Hospital 
e Department of Rheumatology, Medical University of Graz 
f Therakos, Inc, Exton 
g Department of Rheumatology, University of Toronto 
h Huntington Memorial Hospital, Pasadena 
i Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia 
j Department of Dermatology, Yale University School of Medicine, New Haven 

Reprint requests: Robert Knobler, MD, Division of Special & Environmental Dermatology, Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

Vienna and Graz, Austria; Geneva, Switzerland; Stanford and Pasadena, California; New Haven, Connecticut; Morristown, New Jersey; Exton and Philadelphia, Pennsylvania; and Toronto, Ontario, Canada

Abstract

Background

Systemic sclerosis is a multisystemic connective tissue disease with marked involvement of the skin and joints for which few effective evidence based therapies are available. To further investigate the efficacy of extracorporeal photochemotherapy on early aggresive cutaneous disease, a randomized, double-blind, placebo-controlled trial was performed.

Objective

Our aim was to evaluate the efficacy of photopheresis in the treatment of patients with systemic sclerosis (scleroderma).

Methods

This randomized, double-blind, placebo-controlled clinical trial was conducted at 16 investigational sites in the United States, Canada, and Europe. Sixty-four patients with typical clinical and histologic findings of scleroderma, of less than 2 years’ duration, were studied. Patients did not receive any other concomitant treatment for scleroderma. Patients were randomized to receive either active or sham photopheresis treatment on two consecutive days monthly for 12 months. Severity of skin (skin scores assessed in 22 body regions) and joint involvement (60 joints examined for contractures) were assessed on a monthly basis.

Results

A statistically significant improvement in skin scores as compared with baseline was observed at 6 months (P = .0024) and 12 months (P = .008) among those who received active photopheresis, but not among those who received sham photopheresis. Comparison of skin scores between the two study arms did not achieve statistical significance because of the small sample size of the study arms. Joint involvement was also significantly improved after 6 months (P = .002) and 12 months (P = .001) of active photopheresis when compared with baseline.

Limitations

The study lacks sufficient statistical power to reveal a significant difference in skin and joint manifestations between the active and sham photopheresis arms.

Conclusion

Photopheresis induced significant improvement of skin and joint involvement in patients with scleroderma of recent onset; however, any effect when compared with sham treatment and a possible placebo effect may be modest.

Le texte complet de cet article est disponible en PDF.

Plan


 Funding sources: Therakos, Inc.
Disclosure: Drs Knobler and Bisaccia are consultants for Therakos; Dr Strobl is an employee of Therakos, Inc.


© 2006  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 54 - N° 5

P. 793-799 - mai 2006 Retour au numéro
Article précédent Article précédent
  • Eczema herpeticum patients needed for referral
| Article suivant Article suivant
  • Fibrous hamartoma of infancy: An Italian multi-institutional experience
  • Elena Carretto, Patrizia Dall’Igna, Rita Alaggio, Fortunato Siracusa, Claudio Granata, Andrea Ferrari, Giovanni Cecchetto

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.